Search all medical codes

FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and promoter methylation status)

CPT4 code

Name of the Procedure:

FMR1 (Fragile X Mental Retardation 1) Gene Analysis; Characterization of Alleles (e.g., Expanded Size and Promoter Methylation Status)

Summary

This procedure involves a genetic test designed to analyze the FMR1 gene for abnormalities, such as expanded trinucleotide repeats and methylation status, which are indicative of fragile X syndrome, a genetic disorder that causes intellectual disability.

Purpose

The primary purpose of the FMR1 gene analysis is to diagnose fragile X syndrome, which can lead to developmental delays, learning disabilities, and cognitive impairment. The goal is to identify mutations that cause fragile X syndrome to provide a definitive diagnosis and guide appropriate clinical management and genetic counseling.

Indications

  • Individuals with unexplained intellectual disability, developmental delay, or autism spectrum disorder.
  • Family history of fragile X syndrome or related genetic disorders.
  • Females with premature ovarian insufficiency or a family history of same.
  • Males with primary ovarian insufficiency or characteristic physical and behavioral features of fragile X syndrome.

Preparation

  • No special preparation like fasting is typically required.
  • A detailed medical family history and pre-test counseling might be advised.
  • Informed consent is usually obtained prior to the procedure.

Procedure Description

  1. Blood Sample Collection: A blood sample is taken from the patient to extract DNA.
  2. DNA Extraction and Amplification: The DNA is extracted from the blood cells and specific segments of the FMR1 gene are amplified using polymerase chain reaction (PCR) techniques.
  3. Size Analysis: The number of trinucleotide repeats in the FMR1 gene is determined through various laboratory techniques like gel electrophoresis.
  4. Methylation Analysis: The promoter region of the FMR1 gene is examined for abnormal methylation patterns using methods like methylation-specific PCR or Southern blotting.

Duration

The laboratory analysis may take several days to a few weeks to complete and process.

Setting

The initial blood sample collection is usually done at an outpatient clinic, hospital, or laboratory, while the genetic analysis is performed in a specialized genetic testing laboratory.

Personnel

  • Phlebotomist or nurse for blood draw.
  • Genetic counselors for pre- and post-test counseling.
  • Medical geneticists and laboratory technologists for genetic analysis.

Risks and Complications

  • The risk of complications is minimal and may include slight discomfort or bruising at the blood draw site.
  • Rarely, there might be minor complications like hematoma or infection.

Benefits

  • Accurate diagnosis of fragile X syndrome and related conditions.
  • Helps guide medical management and intervention strategies.
  • Provides valuable information for family planning and genetic counseling.

    Recovery

  • There are no significant recovery requirements for the test itself.
  • Patients can resume their normal activities immediately following the blood draw.

Alternatives

  • Other genetic tests or screenings for different developmental disorders.
  • Clinical evaluation and neuropsychological assessments.
  • Each alternative has its pros and cons concerning specificity, sensitivity, and the scope of information provided compared to FMR1 gene analysis.

Patient Experience

  • The procedure mainly involves a standard blood draw, which some patients might find slightly uncomfortable.
  • Detailed genetic counseling may provide emotional support and comprehensive understanding during and after the test.

    The careful management of the procedure and follow-up in post-diagnosis scenarios ensure the patient’s comfort and provide valuable diagnostic clarity and direction.

Medical Policies and Guidelines for FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and promoter methylation status)

Related policies from health plans

Similar Codes